Global Bi-Specific MAbS Market Share to Reach $15.19 Billion by 2029, Growing at 13.7% CAGR

What market dynamics are playing a key role in accelerating the growth of the bi-specific mabs market?
The bispecific monoclonal antibodies market is predicted to expand due to a rise in cancer and other chronic illnesses. These antibodies, which are created to treat a variety of diseases, including cancer, infections, central nervous system issues, and autoimmune disorders, are seen as more potent that monoclonal antibodies (moAbs) due to their ability to target two or more tumor antigens on cells, thereby preventing the advancement of cancer. For example, the American Cancer Society's Cancer Facts & Figures 2023 report forecasts that there will be approximately 609,820 cancer-related fatalities in the US in 2023. Thus, the escalating prevalence of chronic illnesses, particularly cancer, will likely spur the need for bi-specific MAbs as an effective treatment option.

Get Your Bi-Specific MAbS Market Report Here:
https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

How will the growth rate of the bi-specific mabs market shape industry trends by 2034?
The market size for bi-specific MAbS has seen considerable expansion in the last few years. Increase from $7.83 billion in 2024 to $9.1 billion in 2025 is projected, with a compound annual growth rate (CAGR) of 16.2%. The historic period's growth can be traced back to enhanced healthcare spending, a rise in funding, and government initiatives.

The market size of bi-specific MAbS is projected to expand swiftly in the upcoming years, reaching a value of $15.19 billion by 2029, with a compound annual growth rate (CAGR) of 13.7%. The predicted growth during this period can be associated with the rising incidence of cancer, growing older population, and a surge in chronic illnesses. The key trends expected during this forecast period are emphasis on technological progress, product innovation, alignment towards artificial intelligence, investment in targeted and combination treatment, and strategic collaborations.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What trends are poised to drive the future success of the bi-specific mabs market?
The bi-specific MAbs market is witnessing a surge of substantial investment by companies into various strategic initiatives including partnerships and collaborations, in a bid to expand their product lineup and market reach. Such strategic collaborations are cooperative alliances between two or more organizations aiming to attain shared goals. An illustration of this occurred in October 2022 when Gilead Sciences and MacroGenics, both US-based biopharmaceutical companies, teamed up with an exclusive purpose to develop MGD024. This bispecific antibody, developed using MacroGenics' DART platform, targets CD123 and CD3, and together with two other bispecific research programs, forms the core of this collaboration. The agreement provides Gilead with an exclusive license option for MGD024, a potential treatment for several hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed for reducing cytokine-release syndrome (CRS) and permitting sporadic dosing, potentially resulting in better patient-centric treatment and enhanced clinical outcomes for AML and MDS patients.

Which primary segments of the bi-specific mabs market are driving growth and industry transformations?
The bi-specific MAbS market covered in this report is segmented -

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:
1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3
2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3
3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)
4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X
5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET
6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A
7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

Which geographical regions are pioneering growth in the bi-specific mabs market?
North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the influential players reshaping the bi-specific mabs market landscape?
Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Is Covered In The Bi-Specific MAbS Global Market Report?

•Market Size Forecast: Examine the bi-specific mabs market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the bi-specific mabs market for a structured understanding.
•Key Players Overview: Analyze major players in the bi-specific mabs market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the bi-specific mabs market.
•Segment Contributions: Evaluate how different segments drive overall growth in the bi-specific mabs market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the bi-specific mabs market.
•Industry Challenges: Identify potential risks and obstacles affecting the bi-specific mabs market.
•Competitive Landscape: Review strategic developments in the bi-specific mabs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.